Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Suzanne M. Garland; Mauricio Hernández‐Ávila; Cosette M. Wheeler; Gonzalo Pérez; Diane M. Harper; Sepp Leodolter; Grace Tang; Daron G. Ferris; Marc Steben; Janine T. Bryan; Frank J. Taddeo; Radha Railkar; Mark T. Esser; Heather L. Sings; Micki Nelson; John W. Boslego; Carlos Sattler; Eliav Barr; Laura A. Koutsky

doi:10.1056/nejmoa061760

Key Points

The aim is to evaluate the efficacy of a quadrivalent vaccine in reducing HPV-associated anogenital diseases among young women.
Conducted a randomized trial, detailed in ClinicalTrials.gov NCT00092521.
Focus on incidence rates of HPV-related anogenital diseases.
Significant reduction in the incidence of HPV-associated anogenital diseases among vaccinated participants.

Implication

Randomized trial shows reduced incidence of HPV-related anogenital diseases in young women, indicating effective prevention.

Abstract

The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women. (ClinicalTrials.gov number, NCT00092521 [ClinicalTrials.gov].).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Garland et al. (2007) studied this question.

synapsesocial.com/papers/69d776beaa68b335b4f3199e https://doi.org/10.1056/nejmoa061760

View at Publisher

Ask AI

Bookmark

Share

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Key Points

Implication

Abstract

Discussion

Cite This Study

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading